QRxPharma: Pivotal Catalysts Present Significant Near-Term Upside Potential
- QRXPY has make or break regulatory catalysts occurring within the next 2 months that will bring some much needed attention to an under the radar stock.
- Their product for pain relief product portfolio has potential to be best in class and previous trial data suggests the FDA will approve it this time around.
- Because it is an Australian company, it is very under the radar, thus significant near term upside.
- Unlike many small cap, developmental stage Biotechs, there aren't blatant red flags.